Centessa Pharmaceuticals plc American (CNTA) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CNTA SEC filings page.
Centessa Pharmaceuticals plc American (CNTA) reported $15.0M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Centessa is still a research-led development business: revenue is emerging, but R&D spending and cash outflows remain far larger than revenue.
In FY2025, operating cash flow of-$193.8M nearly matched the net loss of$197.5M , while free cash flow was-$194.2M ; this close agreement indicates that reported losses are translating into cash consumption rather than arising mainly from non-cash charges.
R&D was
The balance sheet is equity-funded: debt-to-equity was 0.2x and liabilities represented
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Centessa Pharmaceuticals plc American's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Centessa Pharmaceuticals plc American held $577.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $193.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Centessa Pharmaceuticals plc American scores 63/100 among other emerging companies.
Centessa Pharmaceuticals plc American had 155M shares outstanding at the end of fiscal year 2025, against 133M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Centessa Pharmaceuticals plc American scores 31/100 among other emerging companies.
Centessa Pharmaceuticals plc American spent $172.2M on research and development in fiscal year 2025, which was 77.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Centessa Pharmaceuticals plc American scores 94/100 among other emerging companies.
Centessa Pharmaceuticals plc American reported revenue of $15.0M in fiscal year 2025, against none in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Centessa Pharmaceuticals plc American scores 78/100 among other emerging companies.
Centessa Pharmaceuticals plc American's operations used $193.8M of cash in fiscal year 2025, against $142.1M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Centessa Pharmaceuticals plc American scores 38/100 among other emerging companies.
Centessa Pharmaceuticals plc American's cash, cash equivalents and investments came to $577.1M at the end of fiscal year 2025, against $160.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Centessa Pharmaceuticals plc American scores 85/100 among other emerging companies.
Centessa Pharmaceuticals plc American passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
Centessa Pharmaceuticals plc American reported a net loss of $197.5M while operations used $193.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Centessa Pharmaceuticals plc American reported an operating loss of $207.7M against $11.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Centessa Pharmaceuticals plc American generated $0 in revenue in Q1 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Centessa Pharmaceuticals plc American's EBITDA was -$79.5M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Centessa Pharmaceuticals plc American reported a net loss of $79.2M in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Centessa Pharmaceuticals plc American earned -$0.52 per diluted share (EPS) in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Centessa Pharmaceuticals plc American held $62.4M in cash against $110.4M in long-term debt as of Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
Centessa Pharmaceuticals plc American's quarterly ROE was -16.3% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is down 9.5 percentage points from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Capital Allocation
Centessa Pharmaceuticals plc American invested $59.9M in research and development in Q1 2026. This represents an increase of 79.1% from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
CNTA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | N/A | $0n/m | $0n/m | $15.0Mn/m | N/A | $0 | $0 |
| R&D Expenses | $59.9M+79.1% | N/A | $41.6M+22.6% | $42.7M+30.2% | $33.4M+47.6% | N/A | $33.9M+20.3% | $32.8M-2.5% |
| SG&A Expenses | $19.9M+61.2% | N/A | $12.2M-2.2% | $11.9M+6.7% | $12.3M-8.2% | N/A | $12.5M+4.0% | $11.2M-16.3% |
| Operating Income | -$79.8Mn/m | N/A | -$53.8Mn/m | -$54.7Mn/m | -$30.8Mn/m | N/A | -$46.4Mn/m | -$44.0Mn/m |
| EBITDA | -$79.5Mn/m | N/A | -$53.6Mn/m | -$54.4Mn/m | -$30.6Mn/m | N/A | -$46.2Mn/m | -$43.7Mn/m |
| Interest Expense | $2.7M-5.1% | N/A | $2.9M+13.0% | $2.9M+14.2% | $2.9M+13.8% | N/A | $2.6M+0.6% | $2.5M+3.1% |
| Income Tax | $850K-39.2% | N/A | $166K-72.7% | $778K+10.4% | $1.4M+190.4% | N/A | $608Kn/m | $705Kn/m |
| Net Income | -$79.2Mn/m | N/A | -$54.9Mn/m | -$50.3Mn/m | -$26.1Mn/m | N/A | -$42.6Mn/m | -$43.8Mn/m |
| EPS (Basic) | -$0.52n/m | -$0.48n/m | -$0.41n/m | -$0.38n/m | -$0.20n/m | -$0.91n/m | -$0.37n/m | -$0.40n/m |
| EPS (Diluted) | -$0.52n/m | -$0.48n/m | -$0.41n/m | -$0.38n/m | -$0.20n/m | -$0.91n/m | -$0.37n/m | -$0.40n/m |
| Diluted Shares (Avg) | 154M+15.4% | N/A | 134M+15.4% | 134M+22.1% | 133M+33.2% | N/A | 116M+20.3% | 109M+15.1% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
CNTA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $641.8M+21.6% | $687.5M+19.2% | $448.3M-26.5% | $492.1M+23.4% | $527.8M+60.8% | $576.8M+60.1% | $609.7M+61.6% | $398.8M+1.5% |
| Current Assets | $348.7M+0.3% | $367.9M-31.4% | $307.7M-45.9% | $300.4M-15.5% | $347.7M+22.2% | $536.4M+70.2% | $568.4M+71.0% | $355.5M+1.5% |
| Cash & Equivalents | $62.4M-40.6% | $61.3M-84.0% | $50.8M-87.1% | $44.2M-65.3% | $105.2M-11.0% | $383.2M+199.3% | $395.0M+130.3% | $127.4M-12.3% |
| Short-Term Investments | $214.2M+19.4% | $233.3M+135.7% | $195.4M+58.3% | $206.5M+23.3% | $179.3M+60.2% | $99.0M-23.0% | $123.4M+12.4% | $167.5M+5.7% |
| Long-Term Investments | $257.1M+83.1% | $282.5Mn/m | $102.8Mn/m | $153.4Mn/m | $140.4Mn/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $154.4M+9.1% | $160.6M-8.3% | $146.7M+32.7% | $147.2M+31.6% | $141.6M+25.3% | $175.3M+41.3% | $110.6M-6.3% | $111.9M-3.8% |
| Current Liabilities | $36.6M+51.1% | $42.9M-26.0% | $29.1M+10.3% | $29.7M+11.0% | $24.2M-11.8% | $58.0M+47.3% | $26.4M-24.5% | $26.8M-21.0% |
| Non-Current Liabilities | $117.8M+0.4% | $117.7M+0.4% | $117.6M+39.7% | $117.5M+38.0% | $117.4M+37.2% | $117.3M+38.6% | $84.2M+1.4% | $85.1M+3.2% |
| Long-Term Debt | $110.4M+1.1% | $110.1M+1.1% | $109.8M+45.1% | $109.5M+43.2% | $109.3M+42.3% | $108.9M+43.9% | $75.7M+2.3% | $76.5M+4.4% |
| Total Equity | $487.3M+26.2% | $526.9M+31.2% | $301.6M-39.6% | $344.9M+20.2% | $386.2M+79.5% | $401.5M+70.0% | $499.1M+92.4% | $287.0M+3.7% |
| Retained Earnings | -$1.3Bn/m | -$1.2Bn/m | -$1.1Bn/m | -$1.1Bn/m | -$1.0Bn/m | -$988.7Mn/m | -$877.4Mn/m | -$834.8Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
CNTA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$72.2Mn/m | -$55.8Mn/m | -$58.3Mn/m | -$22.5Mn/m | -$57.2Mn/m | -$42.8Mn/m | -$21.4Mn/m | -$40.6Mn/m |
| Depreciation & Amortization | $239K+10.1% | $241K+4.8% | $237K+0.4% | $226K-4.2% | $217K-9.6% | $230K-6.5% | $236K-0.8% | $236K-0.4% |
| Stock-Based Compensation | $10.6M+34.0% | N/A | $7.2M-14.9% | $7.9M-7.7% | $7.9M-3.3% | N/A | $8.5M+11.8% | $8.6M+19.4% |
| Capital Expenditures | N/A | $11Kn/m | $234K+588.2% | N/A | N/A | $0-100.0% | $34K-20.9% | $0-100.0% |
| Free Cash Flow | N/A | -$55.8Mn/m | -$58.5Mn/m | N/A | N/A | -$42.8Mn/m | -$21.4Mn/m | -$40.6Mn/m |
| Investing Cash Flow | $42.7Mn/m | -$218.1M-972.5% | $61.9M+37.8% | -$40.0Mn/m | -$222.4M-1426.7% | $25.0Mn/m | $45.0M-7.7% | -$55.5Mn/m |
| Financing Cash Flow | $30.5M+887.3% | $283.4M+9464.6% | $3.4M-98.6% | $1.6M-98.5% | $3.1M-70.6% | $3.0M-53.4% | $246.0M+1568.4% | $105.3M+877508.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CNTA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | -205.2% | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | -174.2% | N/A | N/A | N/A |
| Return on Equity | -16.3%-9.5pp | N/A | -18.2%-9.7pp | -14.6%+0.7pp | -6.8%+10.9pp | N/A | -8.5%+6.4pp | -15.3%-6.3pp |
| Return on Assets | -12.3%-7.4pp | N/A | -12.2%-5.3pp | -10.2%+0.8pp | -5.0%+6.6pp | N/A | -7.0%+3.3pp | -11.0%-4.7pp |
| Current Ratio | 9.53-4.8x | 8.57-0.7x | 10.56-11.0x | 10.12-3.2x | 14.37+4.0x | 9.25+1.2x | 21.52+12.0x | 13.29+2.9x |
| Debt-to-Equity | 0.23-0.1x | 0.21-0.1x | 0.36+0.2x | 0.32+0.1x | 0.28-0.1x | 0.270.0x | 0.15-0.1x | 0.270.0x |
| Liabilities-to-Equity | 0.320.0x | 0.30-0.1x | 0.49+0.3x | 0.430.0x | 0.37-0.2x | 0.44-0.1x | 0.22-0.2x | 0.390.0x |
| Asset Turnover | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.030.0x | N/A | 0.00 | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc American CNTA | FY2025 | $15.0M | -$197.5M | N/A | N/A | 65/100 |
| Telix Pharmaceuticals Limited TLX | FY2025 | $803.8M | -$7.1M | -0.9% | $3.1B | 44/100 |
| Scholar Rock Holding Corporation SRRK | FY2025 | $0 | -$377.9M | N/A | $5.3B | — |
| Immunovant, Inc. IMVT | FY2026 | N/A | -$505.6M | N/A | $6.1B | — |
| Viking Therapeutics, Inc VKTX | FY2025 | $0 | -$359.6M | N/A | $3.2B | — |
Where Centessa Pharmaceuticals plc American Ranks
Frequently Asked Questions
What is Centessa Pharmaceuticals plc American's annual revenue?
Centessa Pharmaceuticals plc American (CNTA) reported $15.0M in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Centessa Pharmaceuticals plc American profitable?
No, Centessa Pharmaceuticals plc American (CNTA) reported a net loss of $197.5M in fiscal year 2025.
What is Centessa Pharmaceuticals plc American's EBITDA?
Centessa Pharmaceuticals plc American (CNTA) had EBITDA of -$206.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Centessa Pharmaceuticals plc American have?
As of fiscal year 2025, Centessa Pharmaceuticals plc American (CNTA) had $61.3M in cash and equivalents against $110.1M in long-term debt.
What is Centessa Pharmaceuticals plc American's return on equity (ROE)?
Centessa Pharmaceuticals plc American (CNTA) has a return on equity of -37.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Centessa Pharmaceuticals plc American's free cash flow?
Centessa Pharmaceuticals plc American (CNTA) recorded an outflow of $194.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Centessa Pharmaceuticals plc American's operating cash flow?
Centessa Pharmaceuticals plc American (CNTA) recorded an outflow of $193.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Centessa Pharmaceuticals plc American's total assets?
Centessa Pharmaceuticals plc American (CNTA) had $687.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Centessa Pharmaceuticals plc American's capital expenditures?
Centessa Pharmaceuticals plc American (CNTA) invested $371K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Centessa Pharmaceuticals plc American spend on research and development?
Centessa Pharmaceuticals plc American (CNTA) invested $172.2M in research and development during fiscal year 2025.
What is Centessa Pharmaceuticals plc American's current ratio?
Centessa Pharmaceuticals plc American (CNTA) had a current ratio of 8.57 as of fiscal year 2025, which is generally considered healthy.
What is Centessa Pharmaceuticals plc American's debt-to-equity ratio?
Centessa Pharmaceuticals plc American (CNTA) had a debt-to-equity ratio of 0.21 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Centessa Pharmaceuticals plc American's liabilities-to-equity ratio?
Centessa Pharmaceuticals plc American (CNTA) had a liabilities-to-equity ratio of 0.30 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Centessa Pharmaceuticals plc American's return on assets (ROA)?
Centessa Pharmaceuticals plc American (CNTA) had a return on assets of -28.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Centessa Pharmaceuticals plc American's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Centessa Pharmaceuticals plc American (CNTA) held $577.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $193.8M over that year. Dividing the one by the other, the reported balance equals about 36 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Centessa Pharmaceuticals plc American's Piotroski F-Score?
Centessa Pharmaceuticals plc American (CNTA) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Centessa Pharmaceuticals plc American's earnings high quality?
Centessa Pharmaceuticals plc American (CNTA) reported a net loss of $197.5M while operations used $193.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Centessa Pharmaceuticals plc American cover its interest payments?
Centessa Pharmaceuticals plc American (CNTA) reported an operating loss of $207.7M against $11.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Centessa Pharmaceuticals plc American?
Centessa Pharmaceuticals plc American (CNTA) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.